Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 20/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.73 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1640708 | 0.87 | KCNH2 (0.64) | HDAC1KCNH2HDAC3 | |
| SCHEMBL1640700 | 0.85 | HDAC1 (1.00) | HDAC1KCNH2HDAC3 | |
| SCHEMBL8241613 | 0.83 | HDAC1 (0.57) | HDAC1KCNH2HDAC3 | |
| SCHEMBL1639854 | 0.82 | HDAC1 (0.77) | HDAC1KCNH2HDAC3 | |
| SCHEMBL1639170 | 0.82 | HDAC1 (0.82) | HDAC1KCNH2HDAC3 | |
| SCHEMBL1640602 | 0.80 | HDAC1 (0.73) | HDAC1KCNH2HDAC3 | |
| SCHEMBL1640606 | 0.80 | HDAC1 (0.77) | HDAC1KCNH2HDAC3 | |
| SCHEMBL1639127 | 0.78 | HDAC1 (0.75) | HDAC1KCNH2HDAC3 | |
| SCHEMBL4069251 | 0.77 | HDAC1 (0.73) | HDAC1KCNH2HDAC3 | |
| SCHEMBL1639059 | 0.76 | HDAC1 (0.69) | HDAC1KCNH2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131041-A1 | SPIROCYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2013-05-23 | — | — | US | claimed |
| US-20090209566-A1 | Spirocyclic Compounds | MERCK SHARP & DOHME LLC | 2009-08-20 | — | — | US | claimed |
| EP-1954698-B1 | SPIROCYCLIC COMPOUNDS AS HDAC INHIBITORS | MERCK & CO INC (US) | 2009-06-24 | — | — | EP | claimed |
| US-20070117824-A1 | Spirocyclic compounds | MERCK SHARP & DOHME LLC | 2007-05-24 | — | — | US | claimed |
| US-20130131041-A1 | SPIROCYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131041-A1 | SPIROCYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131041-A1 | SPIROCYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2013-05-23 | — | — | US | disclosed |
| US-8349825-B2 | Spirocyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349825-B2 | Spirocyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349825-B2 | Spirocyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20110098268-A1 | SPIROCYCLIC COMPOUNDS | MERCK & CO., INC (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110098268-A1 | SPIROCYCLIC COMPOUNDS | MERCK & CO., INC (US) | 2011-04-28 | — | — | US | disclosed |
| EP-1954698-B1 | SPIROCYCLIC COMPOUNDS AS HDAC INHIBITORS | MERCK & CO INC (US) | 2009-06-24 | — | — | EP | disclosed |
| US-7544695-B2 | Spirocyclic compounds | MERCK & CO., INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544695-B2 | Spirocyclic compounds | MERCK & CO., INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544695-B2 | Spirocyclic compounds | MERCK & CO., INC. (US) | 2009-06-09 | — | — | US | disclosed |
| WO-2007061880-A1 | SPIROCYCLIC COMPOUNDS AS HDAC INHIBITORS | MERCK & CO., INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070117824-A1 | Spirocyclic compounds | MERCK SHARP & DOHME LLC | 2007-05-24 | — | — | US | disclosed |
| US-20070117824-A1 | Spirocyclic compounds | MERCK SHARP & DOHME LLC | 2007-05-24 | — | — | US | disclosed |
| US-20070117824-A1 | Spirocyclic compounds | MERCK SHARP & DOHME LLC | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098268-A1 | SPIROCYCLIC COMPOUNDS | BRDT, TXNRD3, HDAC1 | HDAC1 3/4885KCNH2 2416/4885HDAC3 10/4885 |
| US-20090209566-A1 | Spirocyclic Compounds | NR1H2, RORA, NR2E3 | HDAC1 12/4885KCNH2 2541/4885HDAC3 8/4885 |
| US-20070117824-A1 | Spirocyclic compounds | BRDT, TXNRD3, HDAC1 | HDAC1 3/4885KCNH2 2416/4885HDAC3 10/4885 |
| US-20130131041-A1 | SPIROCYCLIC COMPOUNDS | BRDT, TXNRD3, HDAC1 | HDAC1 3/4885KCNH2 2416/4885HDAC3 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.